Teva Pharmaceutical Industries Ltd. (TEVA) and Active Biotech (ACTI.PK) stated that they have amended the marketing and distribution agreement for oral laquinimod, an investigational treatment for relapsing- remitting multiple sclerosis or RRMS.
Under the new deal, Teva extended its marketing and distribution rights to include the Nordic and Baltic regions, previously held by Active Biotech. Active Biotech would receive a higher royalty rate for sales in these territories deal inked in 2004 for sales in the rest of the world, the companies noted.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.